Company Name
Drug
Current Stage
Next Milestone
Collaboration
Last Updated
Arcturus Therapeutics Ltd. (
ARCT)
ARCT-154 and ARCT-165 Covid-19 Vaccines
On Aug. 3, 20121, ARCT-154 and ARCT-165, STARR mRNA Vaccines targeting SARS-CoV-2 Variants of concern, given clearance to move into Phase 1/2 study in Singapore
-
-
08/04/2021
Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ)
BIOKANGTAI COVID-19 Vaccine
-- Approved in China for emergency use on May 14, 2021 -- Phase 3 trial initiated in Malaysia on Jun.21, 2021 -- On Aug.2, 2021, received approval in the Philippines to launch phase 3 trial
-- Seeking to launch clinical trials in more countries and regions in South America, Europe, etc -- Launch trials in Ukraine in August
-
08/03/2021
Direct Biologics
ExoFlo
Two clinical trials evaluating ExoFlo for the treatment of COVID-19-related acute respiratory distress syndrome (ARDS) in inpatient and ICU setting have been completed
-- Commence Phase 1/2 trial for mild-to-moderate COVID-19, called EMOTE COVID-19, later in 2021 -- Start phase 1/2 trial for for Post-Acute COVID-19 Syndrome, dubbed EIPACS, later in 2021
-
08/02/2021
Therapeutic Solutions International, Inc. (
TSOI)
JadiCell
Phase I/IIa trial -- Data reported on May 21, 2021, showed that JadiCell substantially improved survival in end-stage patients with COVID-19 associated Acute Respiratory Distress Syndrome --On Jul.27, 2021, preclinical data was reported, suggesting efficacy of JadiCell in animal model resembling COVID-19 Delta Variant associated lung pathology
Conducting Phase III pivotal trial
-
08/01/2021
BetterLife Pharma Inc. (BETRF.OB)
AP-003
AP-003 given clearance in Chile to enter into phase I/II trial (IN2COVID )
IN2COVID trial set to start in early August
-
08/01/2021
Revive Therapeutics Ltd. (RVVTF.OB)
Bucillamine
Phase 3 trial in mild to moderate COVID-19.
-- The next independent Data and Safety Monitoring Board review of the study in Q3, 2021 -- Enrollment in phase 3 trial to be completed in Q3, 2021
-
07/31/2021
Todos Medical, Ltd.
Tollovir
Phase 2/3 trials of Tollovir for the treatment of non-hospitalized and hospitalized COVID-19 patients to begin in India
-- Enrollment for both trials to begin in Q3, 2021, with data expected in 4Q, 2021 -- Pivotal trial to begin in 4Q, 2021
NLC Pharma
07/31/2021
Augmenta Bioworks
AUG-3387
In vivo preclinical study --Data released on Jul.29, 2021, showed AUG-3387 can neutralize SARS-CoV-2 Delta Variant in infective assays
-- In vivo preclinical efficacy studies to be completed in the coming weeks -- Toxicology studies to start by the end of 2021
TFF Pharmaceuticals Inc. (TFFP)
07/31/2021
Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)